DM-99 has Positive Results Type 1 Diabetes Study
DiaMedica recently announced positive clinical studies using DM-99 in animal clinical studies. DM-99 has the ability to increase new beta cells when given to diabetic lab animals.
The Study Results
“The increased beta cell proliferation led to physiologically important improvements in the diabetic state. Improvements included the restoration of peak levels of plasma insulin to near normal levels (p<0.05) with positive trends of increase in the levels of both pancreatic and plasma insulin, which led to improved blood glucose clearance in a oral glucose tolerance test with DM-99 treatment. On July 8th, DiaMedica reported initial results of the study that included a 68% reduction in fasting blood glucose (p<0.05) with DM-99.” Information retrieved from the report by DiaMedica.
The Future of DM-99
"The ability of DM-99 to significantly increase beta cell replication combined with our earlier data showing the ability of DM-99 to protect against a variety of autoimmune attacks may result in a first in class treatment for type I diabetes", stated Mr. Rick Pauls, President and CEO of DiaMedica. "We are currently developing DM-199, a novel recombinant and humanized form of DM-99 for commercialization."
Human Clinical Trails
Human clinical trails are awaiting approval. DM-99 if successful in humans will not only improve the blood sugar levels of diabetics but also help the immune system to fight off autoimmune attacks that can lead to or make diabetes worse.